Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.

Trial Profile

Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2018

At a glance

  • Drugs Letrozole (Primary) ; Ribociclib (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms NEOLBC
  • Most Recent Events

    • 06 Feb 2018 Planned End Date changed from 1 Nov 2024 to 1 Feb 2025.
    • 06 Feb 2018 Planned primary completion date changed from 1 Apr 2020 to 1 Jul 2020.
    • 06 Feb 2018 Planned initiation date changed from 1 Nov 2017 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top